subacut
scleros
panenceph
sspe
progress
lethal
complic
measl
caus
particular
mutant
measl
viru
mev
persist
brain
despit
high
level
neutral
antibodi
address
hypothesi
antigen
drift
involv
pathogenet
mechan
sspe
analyz
antigen
alter
mev
envelop
hemagglutinin
protein
mevh
found
patient
sspe
relat
major
circul
mev
genotyp
aim
obtain
cdna
mevh
gene
tissu
taken
brain
autopsi
deceas
person
sspe
short
month
averag
year
long
year
diseas
cours
recombin
mev
substitut
mevh
gene
gener
revers
genet
system
viru
neutral
assay
panel
antimevh
murin
monoclon
antibodi
mab
vaccineimmun
mous
antimevh
polyclon
sera
perform
determin
antigen
related
function
receptorbind
analysi
sspe
mevh
show
activ
manner
similar
panel
wildtyp
virus
sspe
virus
show
alter
antigen
profil
genotyp
f
sspe
case
except
intact
antigen
structur
genotyp
f
sspe
show
enhanc
neutral
mab
target
antigen
site
iia
genotyp
recent
report
antigen
alter
genotyp
epitop
map
neutral
mab
reveal
new
antigen
site
mevh
design
intermedi
posit
previous
defin
antigen
site
ia
ib
conclud
sspecaus
virus
show
similar
antigen
properti
current
circul
mev
genotyp
absenc
direct
correl
antigen
chang
predisposit
certain
genotyp
caus
sspe
lend
support
propos
antigen
drift
pathogenet
mechan
sspe
data
curat
miguel
ngel
formal
analysi
miguel
ngel
fund
acquisit
stephen
j
russel
investig
miguel
ngel
methodolog
miguel
ngel
project
administr
miguel
ngel
resourc
claud
p
muller
stephen
j
russel
softwar
miguel
ngel
supervis
stephen
j
russel
valid
miguel
ngel
stephen
j
russel
visual
miguel
ngel
hemagglutininspecif
neutral
sspe
virus
plo
one
http
doi
measl
viru
mev
singlestrand
negativesens
rna
viru
member
paramyxovirida
famili
genu
morbilliviru
caus
agent
measl
envelop
hemagglutinin
glycoprotein
mev
interact
cellular
receptor
determin
viru
pathogenesi
viru
initi
infect
respiratori
tract
infect
resid
immun
cell
express
receptor
signal
lymphocyt
activ
molecul
slam
next
mev
transfer
local
lymph
node
spread
system
organ
tissu
cell
fusion
form
syncytia
known
warthinfinkeldey
cell
airborn
transmiss
result
cough
sneez
induc
damag
mevinfect
cell
epithelium
intrins
lymphotrop
natur
mev
produc
transient
sever
immunosuppress
common
measl
complic
mev
interstiti
pneumon
giant
cell
pneumonia
otiti
media
diarrhea
although
mev
highli
neurotrop
viru
patient
lethal
central
nervou
system
complic
form
acut
measl
postinfect
dissemin
encephalomyel
measl
inclusionbodi
enceph
immunocompromis
person
subacut
scleros
panenceph
sspe
sspe
fatal
complic
mev
infect
typic
aris
year
acut
measl
incid
sspe
recent
report
high
children
younger
year
unit
state
sspe
caus
common
acut
mev
strain
singl
point
entri
invad
progress
dissemin
throughout
brain
viru
present
onset
sspe
symptom
howev
differ
substanti
origin
mev
strain
refer
mutant
sspe
viru
abnorm
high
concentr
mevspecif
neutral
antibodi
serum
cerebrospin
fluid
hallmark
sspe
diagnosi
spite
howev
immun
respons
ineffect
clear
viru
brain
long
suggest
antigen
drift
role
sspe
pathogenesi
fact
wildtyp
genotyp
show
distinct
signatur
antigen
determin
comparison
genotyp
prompt
us
review
longheld
hypothesi
antigen
drift
viral
persist
mev
envelop
hemagglutinin
protein
mevh
major
target
virusneutr
antibodi
aris
infect
mev
subject
increas
immunolog
pressur
gener
virus
contain
mevh
gene
found
sspe
autopsi
case
aim
investig
hypothesi
antigen
drift
involv
pathogenesi
sspe
analyz
antigen
alter
mevh
found
deced
sspe
relat
major
circul
mev
genotyp
protect
mev
infect
correl
best
antimevh
antibodi
focus
analysi
glycoprotein
brain
autopsi
materi
deced
sspe
madrid
spain
sspe
diseas
cours
patient
either
short
month
patient
design
averag
year
long
year
tabl
mevh
amino
acid
sequenc
alreadi
report
mevh
clone
seri
amino
acid
chang
differ
consensu
sequenc
sever
posit
tabl
predict
mevh
amino
acid
sequenc
sspe
case
belong
genotyp
f
extend
amino
acid
addit
mevh
mutat
ntermin
cytoplasm
tail
inde
sspe
case
mevh
could
detect
western
blot
antibodi
mevh
cytoplasm
tail
fig
amino
acid
sequenc
mevh
genotyp
predict
lack
nlink
carbohydr
point
mutat
tabl
potenti
nlink
glycosyl
site
pngss
mevh
known
glycosyl
addit
point
mutat
mevh
creat
png
nq
although
potenti
usag
predict
netnglyc
server
thu
investig
glycosyl
statu
mevh
peptidenglycosidas
f
pngase
f
treatment
releas
asparaginelink
oligosaccharid
presenc
pngase
f
mevh
form
complet
deglycosyl
show
ident
migrat
pattern
except
mevh
migrat
slightli
lower
molecular
weight
fig
protein
left
untreat
electrophoret
mobil
mevh
decreas
relat
mevh
result
indic
nglycan
moieti
absent
mevh
genotyp
wherea
precis
biochem
aberr
caus
lower
molecular
weight
current
unknown
confirm
lack
usag
png
introduc
mutat
mevh
genotyp
also
includ
mutat
present
nglycosyl
effici
depend
surround
sequenc
previous
cowork
confirm
glycosyl
png
nl
genotyp
therefor
introduc
mutat
posit
control
experiment
setup
total
surfac
express
level
decreas
mutant
compar
mutant
fig
curious
distinct
doubl
band
mevh
observ
pngase
f
treatment
appar
molecular
mass
kda
fig
highermolecularweight
band
like
correspond
partial
deglycosyl
form
expect
rel
mobil
mutant
decreas
compar
unmodifiedunmut
mevh
increas
mutant
fig
differ
electrophoret
mobil
observ
mutant
overal
result
confirm
nglycan
moieti
absent
mevh
genotyp
interestingli
gel
shift
greater
mevh
mutant
genotyp
mean
sd
kda
vs
kda
despit
type
distinguish
standard
mevh
genotyp
glycan
moieti
fig
glycan
process
correl
mevh
dimer
format
determin
oligomer
state
mevh
genotyp
analyz
sampl
fig
nonreduc
condit
wherea
mevh
genotyp
f
show
band
correspond
monom
dimer
higherord
oligom
mevh
almost
exclus
present
monom
fig
detect
vero
cell
express
human
slam
verohslam
wildtyp
vero
cell
line
mevh
genotyp
induc
syncytia
vero
cell
fig
fusion
assay
fusion
effici
mevh
greatest
quantifi
fusion
activ
difficult
extent
syncytium
format
fig
increas
surfac
express
mevh
exclud
potenti
reason
enhanc
fusogen
mevh
protein
show
compar
effici
surfac
express
fig
investig
whether
cell
fusion
occur
receptorspecif
manner
next
examin
abil
sspe
mevh
speci
induc
fusion
chines
hamster
ovari
cho
cell
express
mev
receptor
syncytia
observ
cho
cell
express
mevh
genotyp
use
rather
show
defect
syncytiuminduc
capac
extent
syncytiumform
activ
mevh
greater
slamdepend
manner
notic
differ
fusogen
observ
cho
cell
express
fig
result
show
sspe
mevh
mediat
fusion
trigger
interact
cellular
receptor
differ
celltocel
fusion
activ
assess
interact
mevh
receptor
slam
fig
experi
includ
wildtyp
mevh
major
circul
mev
genotyp
unfortun
unabl
express
purifi
use
amount
mevh
solubl
protein
fragment
slam
produc
respect
whole
extracellular
domain
igg
fc
region
fuse
receptor
use
purif
via
protein
g
facilit
detect
protein
bound
plasticco
mevh
solubl
mevh
produc
carri
streptag
ii
epitop
ntermin
domain
captur
mevhnativelik
conform
surfac
plastic
well
flagtag
epitop
ctermin
domain
also
attach
control
amount
protein
use
coat
bind
antiflag
antibodi
plasticco
mevh
increas
antibodi
concentr
similar
mevh
form
test
indic
similar
amount
coat
protein
per
well
fig
receptorfc
fusion
protein
use
shape
satur
curv
differ
mevh
genotyp
f
satur
lower
concentr
slam
receptor
genotyp
fig
concentr
higher
nm
bind
valu
indistinguish
among
mevh
form
test
surprisingli
mevh
genotyp
f
show
residu
bind
slam
bind
similar
genotyp
accord
bind
curv
shape
lowbindingaffin
group
compris
genotyp
f
identifi
howev
mevh
genotyp
f
show
residu
bind
result
show
even
though
specif
mevf
mevh
interact
requir
effici
fusion
mevh
sspe
strain
cooper
effici
mevf
genotyp
trigger
cell
fusion
howev
discrep
exist
function
biochem
analys
previous
report
demonstr
mevh
sspe
autopsi
case
remain
function
interact
vari
degre
cellular
receptor
next
assess
syncytiuminduc
capac
context
viru
ie
conjunct
membraneassembl
system
mevhmevfmev
matrix
protein
end
recombin
moraten
virus
built
rescu
mevh
gene
replac
sspe
case
also
use
recombin
moraten
virus
encod
genotypespecif
mevh
gene
previous
describ
compar
fusion
activ
shown
fig
measur
area
syncytia
observ
hour
infect
verohslam
viral
express
mevh
form
show
significantli
differ
syncytiuminduc
capac
specif
mev
encod
genotyp
mevh
show
superior
syncytiuminduc
capac
relat
clade
p
genotyp
p
genotyp
f
sspe
case
p
even
though
mev
encod
genotyp
aspecif
mevh
induc
syncytia
verohslam
via
slam
virus
encod
mevh
sspe
slam
receptor
cell
use
show
better
syncytiuminduc
capac
p
p
respect
howev
differ
signific
genotyp
exclud
analysi
fig
address
whether
differ
fusion
activ
due
differ
incorpor
mevh
mevf
protein
virion
assess
protein
composit
recombin
virus
western
blot
fig
illustr
plaqueform
unit
pfu
equat
similar
level
mev
nucleocapsid
mevn
express
slight
decreas
band
correspond
green
fluoresc
protein
gfp
transgen
locat
upstream
mevn
cistron
observ
sspe
viru
compar
decreas
mevf
express
also
detect
viru
argu
signific
differ
express
across
recombin
virus
case
mevh
express
wherea
compar
amount
observ
mev
signal
absent
mev
sspe
use
antimevh
cytoplasm
tail
antibodi
observ
fig
contrast
mevh
express
appar
increas
latter
viru
togeth
sspe
viru
antimev
globular
head
mab
use
instead
overal
mevh
sspe
case
least
fusogen
nonssp
case
incorpor
effici
virion
result
transientexpress
assay
protein
bind
experi
indic
function
activ
viral
glycoprotein
retain
context
viru
mev
select
vitro
escap
neutral
multipl
neutral
antibodi
patient
sspe
increas
serum
level
antimev
antibodi
evalu
sspe
mevh
antigen
profil
togeth
wildtyp
genotyp
fig
aim
use
panel
antimevh
neutral
antibodi
cover
immunogen
epitop
fig
individu
neutral
curv
monoclon
antibodi
mab
recombin
mev
contain
mevh
gene
genotyp
moraten
vaccin
strain
wildtyp
sspe
case
f
sspe
case
shown
fig
mab
target
antigen
site
ia
iii
neutral
recombin
mev
test
neutral
potenc
greatest
site
iii
follow
site
ibn
site
ia
antigen
site
characterist
doserespons
curv
slope
except
mab
genotyp
residu
resist
observ
neutral
heterogen
shown
genotyp
mab
specif
noos
antigen
site
use
wherea
mab
neutral
genotyp
mab
none
antibodi
show
neutral
activ
genotyp
sspe
mev
demonstr
complet
absenc
antigen
site
howev
western
blot
nonneutr
noosespecif
antibodi
could
still
recogn
mevh
effici
similar
mevh
sensit
neutral
noosetarget
antibodi
fig
noos
antigen
site
looplik
structur
form
disulfid
bridg
cystein
substitut
mevh
would
complet
destroy
structur
antigen
site
thu
facilit
complet
escap
neutral
class
antibodi
confirm
introduc
point
mutat
mevh
genotyp
rescu
correspond
viru
neutral
curv
show
complet
resist
noosetarget
neutral
antibodi
sensit
antibodi
target
differ
antigen
site
remain
unchang
ie
fig
sspe
viru
also
neutral
mab
target
antigen
site
iia
iib
antigen
pattern
also
observ
viru
also
escap
neutral
mab
mab
togeth
markedli
distinguish
sspe
case
genotyp
f
sspe
virus
differ
follow
mutat
mevh
globular
head
tabl
mab
also
fail
neutral
genotyp
fig
discern
antigen
determin
target
mab
gener
panel
recombin
mev
featur
point
mutat
found
resist
genotyp
also
gener
mev
possess
addit
glycosyl
site
nd
shown
escap
neutral
mab
neutral
data
indic
target
yet
new
antigen
site
design
antigen
site
f
intermedi
locat
previous
defin
antigen
site
ia
ib
fig
addit
nd
singlepoint
mutat
present
genotyp
sspe
respect
render
recombin
mev
resist
neutral
recent
report
mutat
confer
enhanc
suscept
neutral
antigen
site
iiatarget
mab
interestingli
f
viru
possess
mutat
show
increas
neutral
sensit
mab
confirm
respons
phenotyp
introduc
mutat
vaccin
genotyp
mevh
gene
assess
neutral
sensit
wherea
differ
neutral
sensit
observ
nearbyloc
antigen
site
iibtarget
antibodi
enhanc
neutral
activ
observ
fig
result
broaden
previou
find
genotyp
might
show
enhanc
sensit
neutral
antigen
site
iiatarget
mab
via
point
mutat
amino
acid
recombin
virus
shield
nl
unshield
escap
neutral
fig
overal
correl
diseas
time
cours
sspe
tabl
antigen
mutabl
drawn
neutral
assay
result
viru
neutral
polyclon
antibodi
could
influenc
differ
neutral
effici
variou
antigen
site
togeth
presenc
immunodomin
antigen
site
mab
previous
use
deriv
mice
thu
use
polyclon
antimevh
mous
sera
induc
vaccin
adenoviru
encod
genotyp
edmonston
strain
mevh
directli
measur
contribut
antibodi
repertoir
viru
neutral
use
heatinactiv
mous
serum
min
assess
neutral
activ
recombin
mev
result
show
recombin
mev
escap
polyclon
antimevh
respons
fig
howev
neutral
curv
sspe
form
shift
nonsignificantli
right
relat
virus
ie
decreas
neutral
potenc
sinc
viru
superior
escap
multipl
mab
number
epitop
lack
mevh
preclud
immun
evas
howev
particular
pattern
sensit
mab
neutral
might
affect
overal
neutral
polyclon
antibodi
main
conclus
current
studi
sspe
virus
equal
sensit
neutral
current
circul
wildtyp
mev
strain
work
provid
direct
concret
evid
mevh
found
brain
deced
sspe
behav
similarli
wildtyp
mevh
form
antigen
chang
occur
diseas
cours
risk
factor
sspe
conclus
base
follow
experiment
evid
first
demonstr
mevh
obtain
direct
sequenc
brain
autopsi
materi
function
despit
extens
amino
acid
substitut
produc
celltocel
fusion
receptorbind
fashion
next
show
sspe
mevh
effici
interact
known
wildtyp
mev
receptor
slam
receptor
use
live
attenu
measl
vaccin
final
built
rescu
recombin
mev
gene
mevh
substitut
sspe
case
found
neutral
sensit
similar
virus
code
mevh
major
circul
mev
genotyp
collect
experiment
evid
strongli
support
overal
concept
antigen
differ
found
sspe
virus
similar
magnitud
current
circul
mev
genotyp
previou
studi
suggest
antigen
drift
mechan
mev
persist
basi
increas
concentr
igg
sspe
sampl
collect
diseas
cours
differenti
reactiv
pattern
neutral
antibodi
sspe
strain
report
invari
publish
mani
year
identif
antigen
differ
among
circul
mev
genotyp
unabl
address
specif
differ
antigen
time
yet
identifi
relev
mev
receptor
ie
year
initi
discoveri
membran
cofactor
receptor
consequ
cell
express
broadli
use
viru
isol
prove
induc
attenu
similarli
test
whether
sspe
strain
develop
classic
mev
strain
immun
select
pressur
complic
difficulti
isol
viru
central
nervou
system
inde
sspe
virus
shown
laboratori
contamin
thu
knowledg
first
mev
gener
revers
genet
mevh
gene
brain
autopsi
sampl
differ
recombin
pseudotyp
virus
express
sspe
glycoprotein
produc
sspe
strain
passag
vero
cell
slam
may
alter
viral
tropism
also
interact
epitheli
receptor
could
investig
case
recombin
virus
rescu
verohslam
cell
slam
first
investig
receptor
interact
use
cotransfect
express
plasmid
system
direct
proteintoprotein
interact
purifi
receptor
experi
allow
us
address
whether
revers
genet
system
base
verohslam
cell
introduc
modif
mevh
glycoprotein
may
alter
tropism
nectin
failur
isol
suffici
amount
mevh
genotyp
may
due
quaternari
structur
oligomer
state
solubl
form
mevh
remain
membraneanchor
form
tempt
specul
lack
higher
oligomer
speci
mevh
genotyp
could
fail
compens
lowaffin
bind
tag
use
avid
lack
clear
relationship
oligomer
statu
surfac
express
syncytiuminduc
capac
mevh
discourag
us
character
point
although
specif
mev
genotyp
associ
higher
risk
sspe
mev
variant
differ
abil
establish
persist
viral
infect
vitro
knowledg
sspe
case
alway
caus
wildtyp
genotyp
vaccin
strain
genotyp
never
encount
extens
search
literatur
could
find
genotyp
f
e
associ
sspe
case
shown
wildtyp
mev
genotyp
may
even
resist
neutral
mab
sspe
virus
unexpectedli
mev
genotyp
neutral
effici
noos
antigen
sitetarget
mab
despit
possess
sever
amino
acid
substitut
region
structur
chang
mevh
context
trimer
protein
complex
mevh
mevf
mev
matrix
protein
convincingli
explain
result
sinc
neutral
sensit
recombin
moraten
viru
express
mevh
genotyp
similar
primari
wildtyp
mev
genotyp
isol
howev
chang
residu
instead
may
alter
specif
epitop
within
noos
antigen
site
rather
whole
mevh
structur
observ
emphas
need
test
differ
antibodi
antigen
site
unclear
certain
mev
genotyp
adopt
mutat
escap
neutral
mab
target
certain
antigen
site
noos
ia
ib
iib
also
introduc
mutat
enhanc
neutral
otherwis
poorli
neutral
mab
antigen
site
iia
ndifon
et
al
observ
influenza
virus
specif
amino
acid
substitut
hemagglutinin
protein
increas
neutral
sensit
escap
variant
previous
gener
mab
similar
phenomena
report
sever
acut
respiratori
syndrom
coronaviru
human
immunodefici
viru
hepat
c
viru
specif
steric
competit
antigen
bind
antibodi
differ
neutral
potenc
mutat
increas
bind
antibodi
low
neutral
potenc
would
decreas
overal
viral
neutral
inde
mevh
antigen
site
iia
low
neutral
effici
locat
adjac
noos
antigen
site
high
neutral
effici
therebi
potenti
lead
decreas
viral
neutral
polyclon
mous
antibodi
would
explain
slight
decreas
sensit
despit
neutral
mab
test
disrupt
structur
noos
antigen
site
appar
effect
polyclonalmedi
neutral
immunodomin
noos
antigen
site
would
offer
plausibl
explan
shift
observ
neutral
curv
polyclon
sera
conclus
although
sspe
virus
show
antigen
differ
neutral
mab
magnitud
antigen
variat
similar
found
wildtyp
mev
genotyp
therefor
conclud
mutat
mevh
sspe
consequ
prerequisit
high
neutral
antibodi
titer
typic
sspe
case
ethic
board
irb
approv
mayo
clinic
need
sinc
conduct
direct
research
involv
human
particip
use
clone
plasmid
deriv
deceas
patient
obtain
autopsi
none
deceas
patient
vulner
popul
donor
next
kin
provid
written
inform
consent
freeli
given
sequenc
encod
aforement
plasmid
alreadi
publish
referenc
throughout
manuscript
african
green
monkey
kidney
vero
cell
verohslam
cell
cultur
dulbecco
modifi
minim
essenti
medium
dmem
hyclon
ge
healthcar
life
scienc
supplement
vv
heatinactiv
fetal
bovin
serum
fb
gibco
mgml
geneticin
corn
cho
cell
cell
cho
cell
line
stabli
express
human
grown
roswel
park
memori
institut
medium
rpmi
corn
supplement
fb
cho
cell
stabli
express
human
slam
cho
cell
stabli
express
human
grown
rpmi
fb
mgml
cell
addit
supplement
antibiot
penicillin
streptomycin
uml
gibco
cell
line
routin
test
mycoplasma
contamin
gene
mevh
sspe
autopsi
case
amplifi
pgem
plasmid
pair
primer
ttaattaaaacttagggtgcaagatcatcgataatg
cacta
gtgggtatgcctgatgt
introduc
paci
spei
restrict
site
underlin
flank
mevh
gene
polymeras
chain
reaction
pcr
product
clone
pcg
vector
sequenc
confirm
mutat
introduc
use
quikchang
lightn
sitedirect
mutagenesi
kit
accord
manufactur
instruct
agil
technolog
gfp
n
plasmid
use
backbon
gener
recombin
mev
mevh
gene
easili
exchang
via
uniqu
paci
spei
site
pcgmevh
plasmid
recombin
virus
rescu
use
standard
protocol
modif
integr
insert
verifi
sequenc
correspond
viru
name
accord
mevh
gene
genotyp
done
sequenc
mevh
mevn
wildtyp
virus
use
genotypespecif
mevh
previous
describ
viru
stock
produc
upon
infect
vero
hslam
cell
multipl
infect
two
day
infect
cell
harvest
viral
particl
releas
freezethaw
cycl
viral
titer
determin
plaqu
assay
verohslam
cell
cell
seed
onto
plate
costar
corp
day
experi
two
hour
transfect
cultur
medium
remov
replac
fresh
medium
without
antibiot
equal
amount
pcg
plasmid
encod
mevf
indic
mevh
mutant
pcgmevh
alon
dilut
optimem
thermofish
onto
plate
anoth
optimem
contain
fugen
hd
promega
ad
well
mixtur
incub
min
solut
ad
cell
fusion
activ
evalu
h
later
hemaquik
stain
fisher
scientif
size
syncytia
quantit
use
nisel
microscop
imag
softwar
nikon
altern
number
nuclei
randomli
chosen
syncytia
count
harvest
protein
lysat
cell
wash
phosphatebuff
salin
pb
lyse
ice
min
ml
ripa
buffer
abcam
contain
halt
proteas
inhibitor
cocktail
thermofish
supernat
contain
clear
lysat
collect
centrifug
rpm
min
aliquot
kept
use
immedi
cell
thermofish
grow
plate
transfect
use
expifectamin
gibco
h
post
transfect
cell
wash
cold
optimem
resuspend
medium
cell
incub
ice
h
mous
antimevh
antibodi
wash
optimem
cell
incub
addit
hour
goat
antimous
igg
hl
crossadsorb
secondari
antibodi
alexa
fluor
thermofish
cell
wash
fix
paraformaldehyd
electron
microscopi
scienc
fluoresc
signal
measur
event
use
facscanto
system
bd
bioscienc
sampl
fraction
nupag
bistri
gel
invitrogen
altern
sampl
incub
without
pngase
f
h
per
manufactur
protocol
new
england
biolab
fraction
stain
simplyblu
safestain
thermofish
protein
transfer
onto
pvdf
membran
use
transblot
turbo
blot
system
biorad
membran
block
nonfat
dri
milktrisbuff
salin
tb
h
room
temperatur
incub
overnight
correspond
primari
antibodi
antimevh
cytoplasm
rabbit
antipeptid
serum
made
kw
peng
mayo
clinic
antimevn
antipeptid
serum
mab
antigfp
cell
signal
technolog
antibodi
sigma
membran
wash
time
tb
contain
tween
incub
h
room
temperatur
follow
secondari
antibodi
antimous
thermofish
antirabbit
thermofish
membran
reveal
supersign
west
pico
chemiluminesc
substrat
thermofish
necessari
blot
strip
perform
restor
western
blot
strip
buffer
thermofish
follow
manufactur
instruct
fulllength
solubl
ectodomain
slam
residu
residu
amplifi
plasmid
encod
slam
sino
biolog
inc
respect
proteinspecif
leader
sequenc
substitut
murin
ig
leader
sequenc
whole
ectodomain
subclon
upstream
cassett
code
human
engin
fc
region
part
express
vector
pfuse
invivogen
proteas
cleavag
sequenc
introduc
end
fc
region
mev
receptorfc
fusion
protein
prepar
transient
transfect
express
system
gibco
protein
secret
cultur
supernat
purifi
affin
chromatographi
hitrap
protein
g
column
ge
healthcar
stepwis
elut
perform
mm
glycin
ph
immedi
neutral
na
po
ph
protein
size
puriti
evalu
reduc
sdspage
analysi
simplyblu
safestain
protein
concentr
determin
bca
protein
assay
thermofish
recombin
solubl
mevh
prepar
previous
describ
mous
antimevh
antisera
gener
immun
adenoviru
express
genotyp
edmonston
strain
mevh
describ
previous
monoclon
mevhspecif
antibodi
use
studi
character
previous
elisa
bind
base
biotinyl
overlap
peptid
andor
escap
mutant
virus
neutral
assay
perform
quadrupl
experi
repeat
least
time
depend
antibodi
verohslam
cell
seed
onto
plate
densiti
cellswel
incub
overnight
antimevh
antibodi
serial
dilut
opti
mem
incub
equal
volum
viru
dilut
pfu
per
virusantibodi
mixtur
incub
h
transfer
cell
min
infect
fb
media
ad
well
plate
incub
h
number
enhanc
green
fluoresc
proteinexpress
syncytiawel
count
use
fluoresc
microscop
experi
repeat
least
time
depend
mab
graphpad
prism
mac
wwwgraphpadcom
use
statist
analysi
oneway
anova
posthoc
tukey
multipl
comparison
use
compar
multipl
group
ic
calcul
nonlinear
regress
virusneutr
curv
